Patents by Inventor Takayuki DEMPO

Takayuki DEMPO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10961493
    Abstract: When mammal cells are administered by using a container whose surface in contact with the mammal cells is formed of a fluororesin material at least partially having a —CF3 terminal group or a container whose surface in contact with the mammal cells is formed of a fluororesin material having a total number of non-fluorinated group terminals and —CF2H group terminals in the fluororesin of 70 or less per 1×106 carbon atoms, or mammal cells are stored or cultured in such a container, the cell adhesion on the container inner surface and the cell survival rate reduction can effectively be suppressed. Therefore, by using these containers, a mammal cell-containing liquid having a high concentration and a high proportion of living cells can be administered, stored or prepared, which contributes to regenerative medicine using the mammal cell-containing liquid (suspension liquid).
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: March 30, 2021
    Assignees: DAIKIN INDUSTRIES, LTD., OTSUKA PHARMACEUTICAL FACTORY, INC.
    Inventors: Tatsuya Higuchi, Kozue Komazawa, Yoshiko Mohara, Takayuki Dempo, Masuhiro Nishimura
  • Publication number: 20190365604
    Abstract: There is provided a container or an equipment having low-protein adsorption properties, to be used for administering, storing, conveying or transporting protein or a composition including protein, or for producing protein or a composition including protein. A container or an equipment for producing protein or a composition including protein, wherein the surface of the container or the equipment in contact with protein or a composition including protein is formed of a fluororesin which is at least one fluororesin selected from a tetrafluoroethylene-hexafluoropropylene-based copolymer and a tetrafluoroethylene-perfluoroalkylvinyl ether-based copolymer, which has a melting point of 320° C. or less and which has a total number of non-fluorinated group terminals and —CF2H group terminals in the fluororesin of 70 or less per 1×106 carbon atoms, has remarkable low-protein adsorption properties.
    Type: Application
    Filed: December 21, 2017
    Publication date: December 5, 2019
    Applicants: Daikin Industries, Ltd., Otsuka Pharmaceutical Factory, Inc.
    Inventors: Kozue KOMAZAWA, Tatsuya HIGUCHI, Koji KIGAWA, Kazuaki OBATA, Takayuki DEMPO, Masuhiro NISHIMURA
  • Publication number: 20180201890
    Abstract: When mammal cells are administered by using a container whose surface in contact with the mammal cells is formed of a fluororesin material at least partially having a —CF3 terminal group or a container whose surface in contact with the mammal cells is formed of a fluororesin material having a total number of non-fluorinated group terminals and —CF2H group terminals in the fluororesin of 70 or less per 1×106 carbon atoms, or mammal cells are stored or cultured in such a container, the cell adhesion on the container inner surface and the cell survival rate reduction can effectively be suppressed. Therefore, by using these containers, a mammal cell-containing liquid having a high concentration and a high proportion of living cells can be administered, stored or prepared, which contributes to regenerative medicine using the mammal cell-containing liquid (suspension liquid).
    Type: Application
    Filed: July 14, 2016
    Publication date: July 19, 2018
    Applicants: Daikin Industries, Ltd., Otsuka Pharmaceutical Factory, Inc.
    Inventors: Tatsuya HIGUCHI, Kozue KOMAZAWA, Yoshiko MOHARA, Takayuki DEMPO, Masuhiro NISHIMURA